BACKGROUND The effect of prior treatment with radiotherapy and/or chemotherapy on the myelotoxicity of samarium lexidronam (Sm 153) in patients with metastatic bone lesions and bone pain was described. METHODS Single-institution retrospective chart review of patients receiving Sm 153. The effect of Sm 153 on peripheral white blood cell (WBC), platelet counts, and change from baseline was calc...

Introduction: Bone pain palliation therapy is a mandate in handling end-stage cancer patients. The development of new ligands with higher stability, better pharmacokinetics and lower unwanted tissue uptakes (liver and GI) is still ongoing. Methods: In this work Lu-177 labeled (3-amino-1-hydroxypropane-1,1-di-yl)-bis-(phosphonate) (Lu-pamidronate; LuPAM ), and (3-amino-1-hydroxybutane-1,1-di-yl)...

Introduction: Various bone palliative therapeutic agents have been developed and widely used for bone metastasis such as Sm-EDTMP. In this study, production, quality control and biodistribution studies of a newly developed therapeutic compound have been presented followed by imaging studies in wild-type rodents. Methods: Sm-TTHMP was prepared starting from Sm-SmCl3, prepared by neutron activati...

Objective(s):In this study, 166Ho-1,2-propylene di-amino tetra(methy1enephosphonicAcid) (166Ho-PDTMP) complex  was prepared as a bone palliation agent. Materials and Methods:The complex was successfully prepared using an in-house synthesized EDTMP ligand and 166HoCl3. Ho-166 chloride was obtained by thermal neutron irradiation (1 × 1013 n.cm-2.s-1) of natural Ho(NO3)3 samples  followed by radio...